telithromycin (Ketek)

a ketolide; semisynthetic derivative of erythromycin with cycling of the C11-12 positions to form a carbamate ring to avoid acquired resistance to macrolides; binds 70S bacterial rRNA, specifically to the 23S part (23S RIBOSOMAL RNA), preventing protein synthesis;

Also Known As:

Networked: 262 relevant articles (48 outcomes, 54 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Rangaraju, M: 10 articles (04/2006 - 01/2001)
2.	Nusrat, Roomi: 9 articles (03/2006 - 05/2004)
3.	Leroy, B: 8 articles (04/2005 - 01/2001)
4.	Carbon, C: 6 articles (04/2006 - 12/2000)
5.	Farrell, David J: 5 articles (03/2009 - 08/2004)
6.	Kohno, Shigeru: 5 articles (03/2008 - 04/2003)
7.	Tellier, Guy: 5 articles (09/2005 - 08/2003)
8.	Zhanel, George G: 4 articles (07/2009 - 01/2002)
9.	Brown, Steven D: 4 articles (01/2008 - 04/2004)
10.	Fogarty, C: 4 articles (04/2006 - 06/2003)

Related Diseases

1.	Pneumonia (Pneumonitis) 07/01/2003 - "Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia." 07/01/2006 - "The results support the efficacy of telithromycin in mild to moderate Legionella pneumonia." 07/01/2006 - "However, few reports have indicated the efficacy of telithromycin in community-acquired pneumonia caused by Legionella species. " 04/01/2006 - "Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia." 10/01/2005 - "Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae."
2.	Respiratory Tract Infections (Respiratory Tract Infection) 11/01/2001 - "Telithromycin achieves high and sustained concentrations in ELF and in alveolar macrophages, while it maintains adequate levels in plasma, providing an ideal pharmacokinetic profile for effective treatment of community-acquired respiratory tract infections caused by either common or atypical, including intracellular, respiratory tract pathogens." 09/01/2001 - "Phase III studies have shown telithromycin to be effective in the treatment of community-acquired upper and lower respiratory tract infections. " 01/01/2005 - "Clinical experience in infectious patients has shown that oral telithromycin 800mg once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections. " 10/01/2004 - "Telithromycin is an effective first-line treatment for mild to moderate respiratory infections in adults." 04/01/2005 - "Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. "
3.	Infections 06/01/2003 - "Telithromycin was also highly effective in patients with infections caused by atypical and/or intracellular pathogens and those at increased risk of morbidity. " 03/01/2004 - "Telithromycin cured the infection in 74% of the young and 67% of the old mice but this difference was not significant. " 12/01/2003 - "To estimate the potential efficacy of telithromycin in the treatment of gynecological infections, a pharmacokinetic study was conducted in 13 Japanese subjects. " 01/01/2007 - "However, there have been no studies on the effects of telithromycin (TEL) on chronic respiratory infection in vivo. " 04/01/2006 - "The objective of this study was to evaluate the in vivo immunomodulatory profile of the first ketolide antibacterial - telithromycin in a murine neutropenic thigh infection model. "
4.	Chronic Bronchitis 03/01/2005 - "Telithromycin for the treatment of acute exacerbations of chronic bronchitis." 06/01/2005 - "Telithromycin, available in an oral formulation, is approved by the US Food and Drug Administration for use in adults for treatment of (1) community-acquired pneumonia due to Streptococcus pneumoniae (including multidrug-resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, Chlamydia pneumoniae, or Mycoplasma pneumoniae; (2) acute exacerbation of chronic bronchitis due to S. " 10/01/2005 - "Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization." 05/01/2003 - "The efficacy and safety of a 5-day regimen of 800 mg telithromycin once daily was compared with a standard 10-day regimen of 500 mg cefuroxime axetil twice daily in a multicentre, randomized, double-blind, parallel-group trial involving 376 patients with acute exacerbations of chronic bronchitis (AECB). " 10/01/2005 - "[Efficacy and safety of extended-release clarithromycin (5-day short-course) vs telithromycin, in acute bacterial exacerbation of chronic bronchitis]."
5.	Maxillary Sinusitis 03/01/2005 - "In a pooled analysis of three large controlled clinical trials involving patients with acute maxillary sinusitis, the bacteriological efficacy of 5- or 10-day treatment with telithromycin and 10-day treatment with comparators was evaluated. " 04/01/2005 - "Clinical and bacteriological efficacy of 5-day telithromycin in acute maxillary sinusitis: a pooled analysis." 04/01/2005 - "The aim of this study was to evaluate the efficacy and tolerance of 5 days of telithromycin (800 mg once a day) in the treatment of bacteriologically proven acute maxillary sinusitis (AMS). " 04/01/2005 - "[Efficacy and safety of telithromycin in the treatment of acute maxillary sinusitis]." 05/01/2002 - "The efficacy and tolerability of oral telithromycin 800 mg once daily for 5 vs. 10 days were assessed in patients with acute maxillary sinusitis (AMS). "

Related Drugs and Biologics

1.	telithromycin (Ketek)
2.	Erythromycin (Erycette)
3.	Penicillins (Penicillin)
4.	Clarithromycin (Biaxin)
5.	Anti-Bacterial Agents (Antibiotics)
6.	Macrolides
7.	Amoxicillin (Wymox)
8.	Anti-Infective Agents (Microbicides)
9.	Azithromycin (Zithromax)
10.	Ketolides

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Nasal Surgical Procedures
4.	Transplantation
5.	Catheters